A recent study has enumerated the following features that characterize patients treated in the emergency department (ED) for acute exacerbation of chronic obstructive pulmonary disease (AECOPD): they commonly arrive by ambulance, have a high admission rate and have significant in-hospital mortality.
A combined triple therapy comprising fluticasone furoate (an ICS*), umeclidinium (a LAMA**), and vilanterol (a LABA***) in a single inhaler significantly lowers the rate of moderate or severe exacerbations compared with dual therapies of either ICS-LABA or LAMA-LABA in patients with symptomatic chronic obstructive pulmonary disease (COPD) and a history of exacerbations, the IMPACT# study shows.
Aclidinium bromide does not increase the risk of major adverse cardiac event (MACE) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) who also had significant cardiovascular (CV) risk factors, according to the phase IV ASCENT COPD* study presented at ATS 2018.
Long-term use of inhaled corticosteroids (ICSs) at daily doses of ≥1,000 µg was associated with a modest but significant increase in nonvertebral fracture risk in patients with chronic obstructive pulmonary disease (COPD), according to a real-world study.
Aspirin use in patients with acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) is associated with lower rates of in-hospital mortality, reduced use of invasive mechanical ventilation and shorter hospital length-of-stay, a study suggests.
Intermittent high-dose glucocorticoids (GCs) therapy does not contribute to an increase in the risk of any, osteoporotic, hip or clinically symptomatic vertebral fractures in patients with chronic obstructive pulmonary disorder (COPD), according to a study. However, current GC use appears to increase the risk of hip and clinically symptomatic vertebral fractures.
Treatment with beta-blockers does not appear to influence lung function, overall respiratory status and safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disorder (COPD), according to data from the TONADO research programme.
There appears to be a high rate of emergency department (ED) admission for acute exacerbation of chronic obstructive pulmonary disease (AECOPD), with patients having significant in-hospital mortality, according to data from the *AANZDEM study. Furthermore, compliance with evidence-based treatments in the ED is suboptimal.
New drug applications approved by US FDA as of 1 - 15 December 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Atezolizumab (Tecentriq®, Roche) a programmed death-ligand 1 (PD-L1) inhibitor, is now approved for the treatment of patients with metastatic non-small cell lung cancer who have diseases progression during or following a platinum-containing therapy.
Almost half of secondary school children who had been diagnosed with asthma had suboptimal asthma control, yet over half of those surveyed did not use their inhalers as prescribed, a recent study found.